R.PR
REGISTERED-PRINCIPAL REGISTER
11/09/2021
Back to search
Official data from USPTO
GRABODY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/21/2023
Trademark type
Combined
Nice classes
5, 42
Filing date
03/21/2020
Registration date
11/09/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/09/2021
Last transaction
04/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
3
Owner type
03
Owner location
Gyeonggi-do, KR
Examiner
ROSEN, BENJAMIN H
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "GRABODY" in which the "Y" is a stylized rendering of an antibody symbol in which the light chain elements of the antibody symbol are of orange color, and in which the heavy chain elements of the antibody symbol as well as the letters "G", "R", "A", "B", "O", and "D" are of black color.
Holders and representatives
Holders
ABL Bio, Inc.
Representatives
Steven J. Hultquist HULTQUIST, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
ophthalmic preparations; ophthalmologic preparations; biopharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for medical or veterinary purposes for the treatment and prevention of cancersneurodegenerative diseasesinfectious diseases; diagnostic reagents for medical or veterinary purposes; biotechnological pharmaceutical preparations for medical purposes for the treatment and prevention of cancersneurodegenerative diseasesinfectious diseases; biological preparations for medical purposes for the treatment and prevention of cancersneurodegenerative diseasesinfectious diseases; antibodies being biological preparations for medical purposes for the treatment and prevention of cancersneurodegenerative diseasesinfectious diseases; pharmaceutical preparations for the treatment of tumors; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations acting on the central nervous system; diagnostic biomarker reagents for medical purposes; pharmaceutical preparations for the treatment of Parkinson's disease; anti-cancer preparations; tumor suppressing agents; immunostimulants; pharmaceutical compositionspharmaceutical preparations for the treatment and prevention of cancersneurodegenerative diseasesinfectious diseases
Class 42
scientific research in the fields of biomedicine; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; provision of medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of technology for biotechnology; biotechnological research; medical research in the field of medicine; scientific research in the field of medicine; laboratory research services relating to pharmaceuticals; scientific research in the field of medicinal products; research and development of vaccines and medicines; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical products development; pharmaceutical research and development; research on the subject of pharmaceuticals; medical and scientific researchconducting testing in the nature of clinical trials of medicines for others; medical and scientific researchconducting studies in the nature of clinical trials of medicines for others; development of cell therapy products; scientific research in the field of pharmaceuticals
Publications
History of USPTO decisions and trademark events.
26 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/24/2021
PUBO
PUBLISHED FOR OPPOSITION
08/24/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/04/2021
OTHE
CASE RETURNED TO EXAMINATION
07/20/2021
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/20/2021
APET
ASSIGNED TO PETITION STAFF
07/12/2021
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
06/25/2021
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
06/24/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/09/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/24/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
10/15/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/15/2020
PUBO
PUBLISHED FOR OPPOSITION
09/15/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/26/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/21/2020
GNRT
NON-FINAL ACTION E-MAILED
04/21/2020
CNRT
NON-FINAL ACTION WRITTEN
04/21/2020
DOCK
ASSIGNED TO EXAMINER
04/21/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/26/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/25/2020
NWAP
NEW APPLICATION ENTERED
03/25/2020
Continuous trademark protection
Get notified about every new filing that threatens GRABODY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.